Utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and patients.
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
Overview
GeneCentric Therapeutics utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. By partnering with the foremost clinical laboratories, in-vitro diagnostic (IVD), pharmaceutical, and biotech companies, GeneCentric can focus on its core strength, exceptional science and clinical studies, building evidence for the utility of its unique assays.
GeneCentric Therapeutics Funding
Sign up to gain insights into GeneCentric Therapeutics funding history, including the funding round, time period, and amount raised.
| Financing Round | Date | Amount | Price per share | Valuation |
|---|---|---|---|---|
| Round | Date | Amount | PPS | Valuation |
| Series D | Jun 18, 2025 | 3M | ||
| Series D | Jun 18, 2025 | 3M | ||
| Series C | Jun 04, 2025 | 2M | ||
| Series B | Dec 22, 2016 | 6M | ||
| Series A | Jul 11, 2014 | 4M | ||
| Series A | Jun 26, 2013 | 3M | ||
| Series Seed | Sep 02, 2011 | 250K |
Access the PPS, Valuation details, and a wealth of other data by signing up. Source: Nasdaq Private Market
Buy
Sign up to view historical trading trends and place an offer.
Sell
Understand share pricing, list anonymously, and benefit from transparent fees.
GeneCentric Therapeutics Management Team
Investors
Labcorp
IAG Capital Partners
Alexandria Venture Investments
Hatteras Venture Partners
GeneCentric Therapeutics Valuations & Financials
View real-time NPM data on GeneCentric Therapeutics stock including daily GeneCentric Therapeutics stock price estimates, valuation history, and historical share price information. Access GeneCentric Therapeutics financing rounds, secondary trade levels, cap table data, and private company comparable transactions. Use NPM's private company valuation database to track GeneCentric Therapeutics pricing across six independent market signals. Looking for private company due diligence data sources on GeneCentric Therapeutics? Get in touch to learn more.
Similar Companies
like GeneCentric Therapeutics
Virta Health
Healthcare & Life Sciences
Online specialty medical clinic focused on reversing type 2 diabetes.
Elligo Health Research
Healthcare & Life Sciences
Connects healthcare sites, sponsors, and patients to streamline clinical trial access through technology and data-driven solutions.
Droplet Biosciences
Healthcare & Life Sciences
Turning surgical drain fluid into powerful, early molecular insights to guide personalized post-surgery cancer care.
Hinge Health
Healthcare & Life Sciences
Digital clinic for back, joint, and muscle pain.
Cerebral
Healthcare & Life Sciences
Telemedicine mental health startup, providing evidence-based therapeutic techniques and medication management.
Eikon Therapeutics
Healthcare & Life Sciences
Uses revolutionary technology to discover novel treatments for life-threatening diseases.
Cedar
Healthcare & Life Sciences
The tech platform uses modern intelligence to improve healthcare financial experiences for everyone.
Resilience
Healthcare & Life Sciences
Operates as technology-focused biomanufacturing company dedicated to broadening access to complex medicines.
FAQ
We have answers
GeneCentric Therapeutics stock does not trade on public stock exchanges. GeneCentric Therapeutics stock is considered a private security and you need to be an accredited investor to trade shares. To invest in GeneCentric Therapeutics stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
GeneCentric Therapeutics Stock does not trade on public stock exchanges. In order to sell GeneCentric Therapeutics shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
GeneCentric Therapeutics does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the NPM Data and Intelligence database from Nasdaq Private Market, you can view GeneCentric Therapeutics share price and other valuable private market data.
Read more about secondary market private company stock prices:
There is no ticker symbol for GeneCentric Therapeutics stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell GeneCentric Therapeutics stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in GeneCentric Therapeutics stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
GeneCentric Therapeutics is a private company and has not had an IPO. There is currently no GeneCentric Therapeutics IPO price. Get started to begin exploring the Nasdaq Private Market Data and Intelligence database and gain access to actionable data related to GeneCentric Therapeutics IPO.
Learn more about Data and Intelligence private company stock data for institutional investors on the on the NPM Data and Intelligence Product Page.
